A Study of MK-2225 in Healthy Participants (MK-2225-003)
NCT06643390
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Sclerosis
Interventions
DRUG:
MK-2225
OTHER:
Placebo
Sponsor
Merck Sharp & Dohme LLC